Peer-Reviewed Publication
Eur J Cancer2026;248117079.September 29, 2026Journal Article
Exploration of tumor genomics associated with prolonged benefit from or resistance to talazoparib monotherapy in patients with metastatic castration-resistant prostate cancer.
Elena Castro1, A Douglas Laird2, Niven Mehra3, Tanya Dorff4, Song Zhao5, Inge van Oort6, Donatello Gasparro7, Fabio Calabrò8, Sandro Pignata9, Lajos Geczi10, Philippe Barthélémy11, Deepak Kilari12, Ryon P Graf13, Hsiang-Chun Chen14, Cynthia G Healy15, Giorgio V Scagliotti16, Jijumon Chelliserry14, Dana Kennedy17, Karim Fizazi18, Johann S de Bono19
1Insituto de Investigación del Hospital Universitario 12 de Octubre (imas12), Madrid, Spain. Electronic address: ecastro.imas12@h12o.es.
2Pfizer Inc., South San Francisco, CA, USA.
3Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands.
4Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
5Medical Oncology, Swedish Cancer Institute, Seattle, WA, USA.
6Department of Urology, University Medical Center Groningen, Groningen, the Netherlands.
7Azienda Ospedaliero-Universitaria di Parma, Oncologia Medica, Parma, Italy.
8IRCCS National Cancer Institute Regina Elena, Rome, Italy.
9Dipartimento Uro-Ginecologico, Istituto Nazionale Tumori di Napoli IRCCS, Fondazione G Pascale, Naples, Italy.
10National Tumor Biology Laboratory, National Institute of Oncology, Budapest, Hungary.
11Medical Oncology Department, University Hospital of Strasbourg, Strasbourg, France.
12Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
13Foundation Medicine, Inc., Boston, MA, USA.
14Pfizer Inc., La Jolla, CA, USA.
15Pfizer Inc., Collegeville, PA, USA.
16Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, Orbassano, Turin, Italy.
17Pfizer Inc., Bothell, WA, USA.
18Centre Oscar Lambret, University of Paris-Saclay, Lille, France.
19The Institute of Cancer Research and Royal Marsden Hospital, London, UK.
Abstract
BACKGROUND: Poly(ADP-ribose) polymerase (PARP) inhibition is synthetically lethal in cells with deleterious alterations in DNA damage response genes involved in homologous recombination repair (HRR). Alterations in HRR genes, including BRCA1/2, have been identified in ~25% of prostate cancer samples and linked with worse clinical outcomes. We explored relationships between tumor genetics and prolo…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans